Evidence map›Paper›PMID 40973914›Full record

ArticleMolecular imaging and biology2025

Preclinical Evaluation of an Anti-EphA2 Minibody-Based ImmunoPET Agent as a Diagnostic Tool For Cancer.

Peggy A Birikorang, H E G Wedaarachchi, Jordan A Smith, Gary Kohanbash, W Barry Edwards

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peggy A BirikorangDepartment of Biochemistry, University of Missouri-Columbia, Missouri-Columbia, MO, 65211, USA.ORCID 0000-0001-8501-1371
H E G WedaarachchiMolecular Imaging and Theranostics Center, University of Missouri-Columbia, Missouri-Columbia, MO, 65203, USA.
Jordan A SmithDepartment of Biochemistry, University of Missouri-Columbia, Missouri-Columbia, MO, 65211, USA.
Gary KohanbashDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, 15213, USA. gary.kohanbash2@chp.edu.ORCID 0000-0002-3953-8022
W Barry EdwardsDepartment of Biochemistry, University of Missouri-Columbia, Missouri-Columbia, MO, 65211, USA. wbe59z@health.missouri.edu.ORCID 0000-0002-6070-8778

Funding

NCI NIH HHS NIH R01 CA244520
6 · The paper itself

Abstract

purposeIn this study, we report the development and characterization of a copper-64 ( PROCEDURES: Recombinantly produced anti-EphA2-Mb was evaluated for purity, stability, affinity, and in vivo target localization. Following bifunctional chelator conjugation, radiolabeling with

resultsAnti-EphA2-Mb produced via recombinant protein expression was pure, stable and had high binding affinity to human EphA2 antigen (K

conclusionOur findings demonstrate that anti-EphA2-Mb is an excellent targeting molecule, and [

Indexed as

NeoplasmsPositron-Emission TomographyReceptor, EphA2AnimalsCell Line, TumorCopper RadioisotopesFemaleHumansImmunoconjugatesMiceMice, NudeTissue DistributionCopper-64Copper RadioisotopesImmunoconjugatesReceptor, EphA2Anti-EphA2 minibody (Mb)High performance liquid chromatography (HPLC)ImmunoPET agentInstant thin layer chromatography (iTLC)Positron-emission tomography (PET imaging)Size-exclusion chromatography (SEC)

Identifiers

PMID40973914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.